Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Agilon Health (AGL) to 50c from $1 and keeps an In Line rating on the shares. Q3 results were weaker than anticipated and the reinstated 2025 guidance suggests a challenging Q4 ahead, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health: Hold Rating Amid Cost Pressures and Uncertain Turnaround Efforts
- Agilon Health Reports Q3 2025 Earnings and Outlook
- Agilon Health: Mixed Q3 Results and Cautious Outlook Warrant Hold Rating
- Agilon Health Reports Q3 2025 Financial Results
- Agilon Health sees FY26 revenue $5.81B-$5.83B, consensus $5.80B